Sandhoff Disease clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 2-20
The study aims to characterize prospectively longitudinal progression of neurological domains in GM1 and GM2 Gangliosidosis patients with high-quality standards (GCP compliant).
Oakland, California and other locations
Our lead scientists for Sandhoff Disease research studies include Paul Harmatz, MD.